Edgewise (EWTX) insider: RSU vesting, sell-to-cover and option grant detailed
Rhea-AI Filing Summary
Edgewise Therapeutics insider activity: Behrad Derakhshan, Chief Business Officer, had RSUs vest and executed related transactions on 08/12/2025. 5,781 restricted stock units vested and were treated as acquired at $0.00. To satisfy tax withholding on those vested RSUs, 2,491 shares were sold in multiple transactions at an average price of $13.3924 (range $13.36–$13.49). Following the transactions the reporting person beneficially owned 23,645 shares of common stock directly. The filing also reports 30,000 newly granted RSUs (vesting beginning 08/12/2026) and a stock option to purchase 180,000 shares at an exercise price of $13.39 (vesting 1/48th monthly beginning 09/12/2025). The newly vested and granted awards are subject to standard service-based vesting schedules.
Positive
- Clear disclosure of vesting, sell-to-cover mechanics and price range ($13.36–$13.49)
- New equity awards (30,000 RSUs and option for 180,000 shares) align executive incentives with shareholders
Negative
- Sell-to-cover resulted in disposition of 2,491 shares, reducing direct holdings
- No forward-looking details on dilution impact or total outstanding share count to contextualize award size
Insights
TL;DR: Officer received standard compensation awards; a sell-to-cover satisfied tax withholding—no discretionary large sale reported.
The Form 4 shows routine equity compensation activity for a named officer. 5,781 RSUs vested and a sell-to-cover of 2,491 shares satisfied tax obligations at an average price of $13.3924. The officer also received 30,000 RSUs (vesting from 08/12/2026) and an option for 180,000 shares at $13.39 with monthly vesting starting 09/12/2025. These movements align with corporate compensation practices and do not by themselves indicate material changes in ownership or control.
TL;DR: Issuer documented routine grants and vesting; disclosure is clear about sell-to-cover and vesting schedules.
The filing discloses the nature and timing of each award, including that the sale of 2,491 shares was a non-discretionary sell-to-cover to meet statutory tax withholding. Grant terms are explicit: one RSU tranche vested on 08/12/2025, another RSU grant vests beginning 08/12/2026, and an option grant vests monthly starting 09/12/2025. From a governance perspective the disclosure meets Section 16 requirements and identifies the reporting relationship (Officer/Chief Business Officer).
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 5,781 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 30,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 180,000 | $0.00 | -- |
| Exercise | Common Stock | 5,781 | $0.00 | -- |
| Sale | Common Stock | 2,491 | $13.3924 | $33K |
Footnotes (1)
- Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.
